// App-Quantinova.ai

Su1924 : EFFICACY AND SAFETY OF ABRILUMAB (AMG 181/MEDI 7183) THERAPY FOR MODERATE TO SEVERE Crohn's DISEASE

Researchers

Presenter

  • Marcoli Cyrille

Principal Investigators

  • Mark Berner Hansen

  • Brian G. Feagan

  • Edward V. Loftus

  • Severine Vermeire

  • Martha L Cruz

  • May Mo

  • Barbara A. Sullivan

  • Walter Reinisch

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

  • University of California, San Francisco, San Francisco, California, United States

  • Gastrenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States

  • University of Copenhagen, Copenhagen E, Denmark

Locations

  • Canada

  • Austria

  • United States

  • Denmark

  • Belgium

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 4

  • Faecal calprotectin

  • Tumor necrosis factor

Drug/Treatment

  • MEDI7183

Outcome

  • Unknown

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved